News - GlaxoSmithKline, Atripla

Filter

Current filters:

GlaxoSmithKlineAtripla

Popular Filters

1 to 25 of 443 results

GSK confirms further misconduct allegations, now in Jordan and Lebanon

17-04-2014

There has been recent publicity on cases of alleged misconduct by UK Pharma giant GlaxoSmithKline employees…

GlaxoSmithKlineJordanMarkets & MarketingPharmaceuticalRegulationRest of the World

FDA finally OKs GlaxoSmithKline’s Tanzeum to treat type 2 diabetes

FDA finally OKs GlaxoSmithKline’s Tanzeum to treat type 2 diabetes

16-04-2014

UK pharma giant GlaxoSmithKline yesterday received the much anticipated approval from the US Food and…

albiglutideDiabetesGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationTanzeumUSA

Prosonix and Mylan in deal for Flixotide and Flovent generics

15-04-2014

Prosonix, a UK-based company which is developing a portfolio of inhaled “Respiratory Medicines by Design,”…

FloventGenericsGlaxoSmithKlineGlobalLicensingMylan LaboratoriesProsonixRespiratory and Pulmonary

GSK faces bribery allegations in Poland

GSK faces bribery allegations in Poland

14-04-2014

UK pharma major GlaxoSmithKline is facing allegations of bribing doctors in Poland, according to the…

BBCGlaxoSmithKlineGSK regional managerLegalMajorMedicinePharmaceuticalPolandPulmonologyRespiratory and PulmonarySeretideUK

GSK’s Tafinlar also no added benefit over vemurafenib, says IQWiG

GSK’s Tafinlar also no added benefit over vemurafenib, says IQWiG

09-04-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

GermanyGlaxoSmithKlineNorthern EuropeOncologyPharmaceuticalPricingRegulationTafinlarvemurafenib

Teva launches first generic Lovaza in USA

Teva launches first generic Lovaza in USA

08-04-2014

Israel-based Teva Pharmaceutical Industries says it has received US Food and Drug Administration approval…

Cardio-vascularGenericsGlaxoSmithKlineLovazaMarkets & MarketingRegulationTeva Pharmaceutical IndustriesUSA

GSK faces fresh allegations of “inproper conduct” in Iraq

GSK faces fresh allegations of “inproper conduct” in Iraq

08-04-2014

UK pharma major GlaxoSmithKline is facing allegations of bribery in Iraq, less than a year after the…

ChinaGlaxoSmithKlineGSKIraqMajorPharmaceuticalRegulationUK

Amgen and GSK end marketing agreement for osteoporosis drug Prolia

Amgen and GSK end marketing agreement for osteoporosis drug Prolia

04-04-2014

World leading independent biotech firm Amgen revealed in a Securities and Exchange Commission filing…

AmgenAnti-Arthritics/RheumaticsBiotechnologyGlaxoSmithKlineLicensingProliaXgeva

GlaxoSmithKline targets strategic investments in Africa

02-04-2014

Speaking at the 5th EU-Africa Business Forum in Brussels this week, Sir Andrew Witty, chief executive…

FinancialGlaxoSmithKlineHealthcarePharmaceuticalRest of the WorldSouth Africa

GSK drops Phase III trial of MAGE-A3 antigen-specific cancer immunotherapeutic in NSCLC

GSK drops Phase III trial of MAGE-A3 antigen-specific cancer immunotherapeutic in NSCLC

02-04-2014

UK pharma major GlaxoSmithKline will stop its MAGRIT trial, a Phase III trial of its MAGE-A3 cancer immunotherapeuticin…

GlaxoSmithKlineMAGE-A3OncologyPharmaceuticalResearchUK

GSK withdraws European marketing authorization for ovarian cancer drug Votrient

GSK withdraws European marketing authorization for ovarian cancer drug Votrient

31-03-2014

UK pharma major GlaxoSmithKline has withdrawn its application to the European Medicines Agency for a…

GlaxoSmithKlineOncologyPharmaceuticalRegulationUKVotrientWomen's Health

ACC 2014: GSK’s darapladib disappoints in Ph III trial

ACC 2014: GSK’s darapladib disappoints in Ph III trial

31-03-2014

UK pharma major GlaxoSmithKline (LSE: GSK) presented disappointing data from its pivotal Phase III STABILITY…

Cardio-vasculardarapladibGlaxoSmithKlinePharmaceuticalResearchUKUSA

GSK acquires remaining 30% of its Indonesian Consumer Healthcare business

GSK acquires remaining 30% of its Indonesian Consumer Healthcare business

28-03-2014

US pharma giant GlaxoSmithKline has acquired full ownership of its Indonesian Consumer Healthcare business…

Asia-PacificGlaxoSmithKlineIndonesiaMergers & AcquisitionsPharmaceuticalProduction

Factors driving oncologists’ prescribing decisions for HER2-positive breast cancer patients

Factors driving oncologists’ prescribing decisions for HER2-positive breast cancer patients

28-03-2014

Efficacy, more than any other factors, drives oncologists’ prescribing of targeted therapies for breast…

AfinitorbuparlisibGlaxoSmithKlineHerceptinMarkets & MarketingNovartisOncologyPerjetaPharmaceuticalRocheTykerb

Mylan prevails in breach of contract case against GlaxoSmithKline

Mylan prevails in breach of contract case against GlaxoSmithKline

27-03-2014

US generics major Mylan reveals that, after a trial in the US District Court for the District of New…

GenericsGlaxoSmithKlineLegalMylan LaboratoriesNeurologicalparoxetinePaxil-CR

GSK announces delay in Mekinist/Tafinlar MAA; EU approval of Eperzan

GSK announces delay in Mekinist/Tafinlar MAA; EU approval of Eperzan

27-03-2014

UK pharma giant GlaxoSmithKline released a couple of news items yesterday, one slightly negative regarding…

DiabetesEperzanEuropeGlaxoSmithKlineMekinistOncologyPharmaceuticalRegulationTafinlar

Novel collaboration to use genomics and big data to drive drug discovery

27-03-2014

A pioneering public-private research initiative between UK pharma giant GlaxoSmithKline, the European…

BiotechnologyEuropeGlaxoSmithKlineResearch

GlaxoSmithKline’s MAGE-A3 fails in Ph III NSCLC trial

GlaxoSmithKline’s MAGE-A3 fails in Ph III NSCLC trial

20-03-2014

There was another setback for UK pharma giant GlaxoSmithKline with its MAGE-A3 antigen specific cancer…

AgenusGlaxoSmithKlineMAGE-A3OncologyPharmaceuticalResearch

Promising mid-stage results for Prosensa’s drisapersen in DMD boys

19-03-2014

Shares of Dutch biotech firm Prosensa Holding rose 3.85% to $7.02 after the firm reported encouraging…

BiotechnologydrisapersenGlaxoSmithKlineProsensaRare diseasesResearch

Positive results from Anoro Ellipta vs Seretide and Advair Diskus in patients in COPD

Positive results from Anoro Ellipta vs Seretide and Advair Diskus in patients in COPD

14-03-2014

GlaxoSmithKline and Theravance today announced positive results from three Phase III studies with their…

Advair DiskusAnoro ElliptaGlaxoSmithKlinePharmaceuticalResearchRespiratory and PulmonarySeretide

1 to 25 of 443 results

Back to top